Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence Study in Healthy Subjects, 2*5 mg Tablets Rivaroxaban Versus 1*10 mg Tablet Rivaroxaban

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male subjects~* 18 to 45 years of age~* Body mass index (BMI) between 18 and 30 kg/m2~Exclusion Criteria:~* Conspicuous findings (medical history, screening)~* History of relevant diseases (internal organs, central nervous system or other organs)~* Medical disorder, condition or history of such that would impair the subject's ability to participate or complete this study in the opinion of the investigator or the sponsor~* Febrile illness within 1 week before the start of the study~* History of severe allergies, non-allergic drug reactions, or multiple drug allergies~* Hypersensitivity to the investigational drug, the control agent and/or to inactive constituents~* Known coagulation disorders, known disorders with increased bleeding risk, known sensitivity to common causes of bleeding

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Rivaroxaban (Xarelto, BAY59-7939) first 2*5 mg, then 1*10 mg (Type: EXPERIMENTAL): Single oral dose of rivaroxaban administered under fasting conditions 2\*5 mg tablet in first intervention period and 1\*10 mg tablet in second intervention period (after washout period)
- Rivaroxaban (Xarelto, BAY59-7939) first 1*10 mg, then 2*5 mg (Type: EXPERIMENTAL): Single oral dose of rivaroxaban administered under fasting conditions 1\*10 mg tablet in first intervention period and 2\*5 mg tablet in second intervention period (after washout period)

Based on this trial design, predict the completion outcome and termination type (if applicable).